Future-proofing HRR testing in mPC
Episode 9. As our understanding of HRR biology advances, how is it reshaping the way we define, test, and treat mPC? Alicia Morgans and Alex Wyatt cover the impact of BRCA2 and other HRR mutations on testing strategies, the expanding role of ctDNA and repeat testing, and the complexities of interpreting results across different platforms. “I think the importance of multidisciplinary care is only increasing in prostate cancer... the complexity of testing is only going to continue increasing,” Wyatt remarks. He reflects on the growing importance of multidisciplinary collaboration as testing becomes more nuanced, sharing practical examples of how clinicians can navigate evolving guidelines and integrate molecular insights into treatment decisions. View transcript.
Chapters
00:27 Impact of HRR mutations on biology
03:14 How is HRR testing evolving in mPC?
07:28 HRR/HRD: Guiding treatment in mPC
09:55 Should we retest patients with mPC?
12:31 mPC care: Multidisciplinary teams
16:30 HRR testing: What’s next?
Meet the guest speaker
Alex Wyatt, MD, DPhil
Alex Wyatt holds the President’s Excellence Chair in Precision Oncology and is an Associate Professor at the University of British Columbia, Canada. He serves as Scientific Director of the Clinical Cancer Genomics Program at BC Cancer, where he is also a Senior Scientist in Basic and Translational Research. In addition, he is a Senior Research Scientist at the Vancouver Prostate Centre. Wyatt co-chairs correlative sciences and tumor biobanking for the Canadian Cancer Trials Group (CCTG), contributing to the design and execution of phase 2–3 clinical trial protocols across Canada.
Disclosures: Advisory boards and/or honoraria from Astellas Pharma, AstraZeneca, Bayer, Janssen, Merck, and Pfizer. Received research funding from ESSA Pharma (institutional), Promontory Therapeutics (institutional), and Tyra Biosciences (institutional).
Developed by EPG Health. This content has been developed independently of the sponsor, Pfizer, which has had no editorial input into the content. EPG Health received funding from the sponsor to help provide healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content. This content is intended for healthcare professionals only.